查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813402

2032 年生育表觀基準化分析市場預測：按成分、技術、應用、最終用戶和地區進行的全球分析

Fertility Epigenetic Benchmarking Market Forecasts to 2032 - Global Analysis By Component (Products and Services), Technology (DNA Methylation, Histone Modification and RNA Sequencing), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球生育表觀遺傳基準化分析市場預計在 2025 年達到 6.5505 億美元，到 2032 年將達到 22.2667 億美元，預測期內的複合年成長率為 19.1%。

生育表觀遺傳基準化分析是對影響生殖健康、胚胎發育和不孕症結果的表觀遺傳標記的研究和分析。它為了解影響不孕症的基因調控、生活方式和環境因素提供了見解。由於不孕症率上升、受孕延遲趨勢以及生殖醫學的進步，這個新興市場正日益受到關注。其應用涵蓋診斷、輔助生殖技術 (ART) 和個人化治療計劃。生物技術、生育診所和基因組學公司之間正在進行的研究與合作正在塑造生育表觀遺傳基準基準化分析的商業化。

根據世界衛生組織統計，全球約有六分之一的人一生中會經歷不孕不育，凸顯了不孕症評估的必要性，而評估是包括基準化分析遺傳基準測試在內的高級診斷的基礎。

全球不孕不育率上升

全球不孕症盛行率的上升是生育表觀遺傳學基準化分析市場發展的關鍵促進因素。生育延遲、環境毒素和生活方式改變等因素都導致了不孕症盛行率的上升。因此，對先進診斷工具和個人化治療方案的需求日益成長。表觀遺傳學分析能夠深入了解基因表現模式，並有助於識別潛在的不孕症問題。這種方法有助於制定個人化介入措施，提高治療效果和患者預後。此外，將表觀遺傳學數據整合到不孕症評估中正成為生殖醫學的標準做法。

患者意識有限

生育表觀遺傳學基準化分析市場的一個重要限制因素是患者對錶觀遺傳學檢測的益處和可用性缺乏認知。許多人仍然不了解表觀遺傳因素如何影響不孕症和生殖健康。這種認知的缺乏可能導致診斷延誤，並錯失早期療育的機會。教育工作和宣傳宣傳活動對於讓患者了解表觀遺傳因素在生育治療中的重要性至關重要。病患知識的提升可以推動對表觀遺傳學檢測和個人化生育治療的需求。

生物科技與不孕症診所的合作

生技公司和生育診所擁有越來越多的合作機會，可以推動生育表觀遺傳學基準基準化分析領域的發展。夥伴關係可以促進整合表觀遺傳學見解的創新診斷工具和治療方法的發展。此類合作可以提高不孕症評估的準確性和治療的有效性。此外，共同努力可以促進知識和資源共用，加速生殖醫學的研究和發展。此類夥伴關係有可能透過提供個人化和精準的解決方案，徹底改變生育治療。

公眾對表觀遺傳干預的懷疑

生育表觀遺傳學基準化分析市場面臨的一個突出威脅是社會對表觀遺傳學介入的安全性和有效性的質疑。對改變表觀遺傳因素的長期影響和倫理影響的擔憂，可能會阻礙患者選擇此類治療。這種質疑可能會阻礙基於表觀遺傳學的不孕症治療的廣泛應用。透過透明的溝通、嚴格的臨床試驗和倫理準則來解決這些問題，對於建立公眾的信任和接受至關重要。

COVID-19的影響：

新冠疫情對生育表觀遺傳學基準化分析市場產生了多方面的影響。這場危機導致生育治療中斷，選擇性手術暫停，影響了病患的醫療服務。此外，疫情也加劇了壓力水平和經濟不確定性，影響了生育決策，並推遲了生育計畫。然而，這場危機加速了遠端醫療和遠距會診在生育治療的應用。此外，疫情凸顯了生殖健康韌性的重要性，這可能會推動未來對創新生育治療解決方案的投資。

預計預測期內產品細分市場規模最大

預計該產品細分市場將在預測期內佔據最大的市場佔有率。此細分市場涵蓋各種診斷工具、試劑和試劑套件，這些產品對於不孕症評估中的表觀遺傳學分析至關重要。個人化不孕症治療需求的不斷成長以及表觀遺傳學檢測融入臨床常規是推動該細分市場成長的主要因素。此外，產品開發的進步以及更有效率、更人性化的診斷工具的推出預計將進一步推動市場發展。

預計在預測期內，RNA 定序部分將以最高的複合年成長率成長。

RNA測序領域預計將在預測期內呈現最高成長率。 RNA定序能夠全面分析基因表現，為不孕症的分子機制提供寶貴見解。 RNA定序在生殖醫學研究中的應用日益廣泛，其在識別不孕症生物標記方面的潛力正在推動其普及。此外，RNA定序技術的進步和成本的下降使得這種方法在臨床環境中更加普及，從而促進了其快速成長。

佔比最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。這一優勢得益於該地區先進的醫療基礎設施、高昂的醫療成本以及對研發的高度重視。此外，不孕症盛行率的上升以及對個人化不孕症治療的需求不斷成長，也推動了市場的成長。該地區成熟的生物技術產業和監管支持進一步促進了創新不孕症治療方案的採用，從而鞏固了其在市場上的主導地位。

複合年成長率最高的地區：

預計在預測期內，亞太地區生育表觀遺傳學基準化分析市場將迎來最高的複合年成長率。不孕症上升、生殖健康意識增強以及醫療基礎設施的進步等因素促成了這一快速成長。該地區龐大的人口基數和不斷發展的社會經濟經濟狀況正在推動對生育治療服務和個人化治療的需求。此外，政府在生物技術研究方面的舉措和投資正在推動表觀遺傳學技術在生育治療領域的創新和應用，使亞太地區成為重要的成長中心。

成分

  • 產品
  • 服務

提供免費客製化：

訂閱此報告的用戶可獲得以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球生育表觀遺傳基準基準化分析市場（按組成部分）

  • 產品
    • 套件和試劑
    • 設備及配件
  • 服務
    • DNA甲基化分析
    • 組蛋白修飾分析
    • 非編碼RNA分析
    • 染色質結構分析

6. 全球生育表觀遺傳基準基準化分析市場（依技術）

  • DNA甲基化
    • 亞硫酸氫鹽定序
    • 甲基化DNA免疫沉澱定序（MeDIP-Seq）
    • 其他DNA甲基化技術
  • 組蛋白修飾
    • 染色質免疫沉澱分析法（ChIP）
    • 組蛋白甲基化分析
    • 組蛋白乙醯化分析
  • RNA定序

7. 全球生育表觀遺傳基準基準化分析市場（按應用）

  • 男性不孕
  • 女性不孕症
  • 輔助生殖技術（ART）
    • 體外受精（IVF）
    • 卵細胞質內單一精蟲顯微注射術（ICSI）
    • 胚胎胚胎著床前基因檢測（PGT）
  • 預測診斷和預後

8. 全球生育表觀遺傳基準基準化分析市場（依最終用戶）

  • 不孕不育診所和醫院
  • 學術和研究機構
  • 製藥和生物技術公司
  • 診斷實驗室
  • 合約研究組織（CRO）

9. 全球生育表觀基準化分析市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Illumina
  • Thermo Fisher Scientific
  • Merck KGaA
  • QIAGEN
  • F. Hoffmann-La Roche
  • PacBio
  • Danaher
  • Bio-Rad Laboratories
  • Promega
  • New England Biolabs
  • Zymo Research
  • Hologic
  • Active Motif
  • Chroma Medicine
  • CooperSurgical
  • Inherent Biosciences
  • Vitrolife
  • Ferring Pharmaceuticals
Product Code: SMRC30851

According to Stratistics MRC, the Global Fertility Epigenetic Benchmarking Market is accounted for $655.05 million in 2025 and is expected to reach $2226.67 million by 2032 growing at a CAGR of 19.1% during the forecast period. Fertility epigenetic benchmarking is the study and analysis of epigenetic markers that influence reproductive health, embryo development, and fertility outcomes. It provides insights into genetic regulation, lifestyle impacts, and environmental factors affecting fertility. This emerging market is gaining attention due to rising infertility rates, delayed parenthood trends, and advancements in reproductive medicine. Applications span diagnostics, assisted reproductive technologies (ART), and personalized treatment planning. Ongoing research and collaborations between biotech, fertility clinics, and genomics firms are shaping the commercialization of fertility epigenetic benchmarking.

According to WHO, about 1 in 6 people worldwide experience infertility during their lifetime, highlighting the scale of fertility assessment needs that underpin advanced diagnostics, including epigenetic benchmarking.

Market Dynamics:

Driver:

Rising infertility rates globally

The escalating prevalence of infertility worldwide is a significant driver for the fertility epigenetic benchmarking market. Factors such as delayed childbearing, environmental toxins, and lifestyle changes contribute to this rise. Consequently, there is an increasing demand for advanced diagnostic tools and personalized treatment options. Epigenetic profiling offers insights into gene expression patterns, aiding in the identification of potential fertility issues. This approach facilitates tailored interventions, enhancing treatment efficacy and patient outcomes. Moreover, the integration of epigenetic data into fertility assessments is becoming a standard practice in reproductive medicine.

Restraint:

Limited awareness among patients

A significant restraint in the fertility epigenetic benchmarking market is the limited awareness among patients regarding the benefits and availability of epigenetic testing. Many individuals remain uninformed about how epigenetic factors influence fertility and reproductive health. This lack of awareness can lead to delayed diagnoses and missed opportunities for early intervention. Educational initiatives and awareness campaigns are essential to inform patients about the importance of epigenetic factors in fertility. Increasing patient knowledge can drive demand for epigenetic testing and personalized fertility treatments.

Opportunity:

Collaboration between biotech and fertility clinics

There is a growing opportunity for collaboration between biotechnology companies and fertility clinics to advance the field of fertility epigenetic benchmarking. Partnerships can lead to the development of innovative diagnostic tools and therapies that integrate epigenetic insights. Such collaborations can enhance the accuracy of fertility assessments and the effectiveness of treatments. Additionally, joint efforts can facilitate the sharing of knowledge and resources, accelerating research and development in reproductive medicine. These partnerships have the potential to revolutionize fertility care by offering personalized and precise solutions.

Threat:

Public skepticism of epigenetic interventions

A notable threat to the fertility epigenetic benchmarking market is public skepticism regarding the safety and efficacy of epigenetic interventions. Concerns about the long-term effects and ethical implications of modifying epigenetic factors can deter patients from opting for such treatments. This skepticism may hinder the widespread adoption of epigenetic-based fertility solutions. Addressing these concerns through transparent communication, rigorous clinical trials, and ethical guidelines is crucial to build public trust and acceptance.

Covid-19 Impact:

The COVID-19 pandemic has had a multifaceted impact on the fertility epigenetic benchmarking market. The crisis led to disruptions in fertility treatments and a temporary halt in elective procedures, affecting patient access to care. Moreover, the pandemic heightened stress levels and economic uncertainties, influencing reproductive decisions and delaying family planning. However, the crisis also accelerated the adoption of telemedicine and remote consultations in fertility care. Additionally, the pandemic underscored the importance of resilience in reproductive health, potentially driving future investments in innovative fertility solutions.

The products segment is expected to be the largest during the forecast period

The products segment is expected to account for the largest market share during the forecast period. This segment encompasses a wide range of diagnostic tools, reagents, and kits essential for epigenetic analysis in fertility assessments. The increasing demand for personalized fertility treatments and the integration of epigenetic testing into routine clinical practice are key factors driving the growth of this segment. Moreover, advancements in product development and the introduction of more efficient and user-friendly diagnostic tools are expected to further propel the market.

The RNA sequencing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the RNA sequencing segment is predicted to witness the highest growth rate. RNA sequencing allows for comprehensive analysis of gene expression profiles, providing valuable insights into the molecular mechanisms underlying fertility. The increasing application of RNA sequencing in reproductive health research and its potential to identify biomarkers for fertility are driving its adoption. Additionally, technological advancements and decreasing costs associated with RNA sequencing are making this approach more accessible to clinical settings, contributing to its rapid growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. This dominance is attributed to the presence of advanced healthcare infrastructure, high healthcare expenditure, and a strong focus on research and development in the region. Additionally, the increasing prevalence of infertility and the growing demand for personalized fertility treatments are propelling market growth. The region's well-established biotechnology sector and regulatory support further enhance the adoption of innovative fertility solutions, solidifying its leading position in the market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR in the fertility epigenetic benchmarking market. Factors such as rising infertility rates, increasing awareness about reproductive health, and advancements in healthcare infrastructure contribute to this rapid growth. The region's large population base and evolving socio-economic conditions are driving the demand for fertility services and personalized treatments. Moreover, government initiatives and investments in biotechnology research are fostering innovation and adoption of epigenetic technologies in fertility care, positioning Asia Pacific as a key growth hub.

Key players in the market

Some of the key players in Fertility Epigenetic Benchmarking Market include Illumina, Thermo Fisher Scientific, Merck KGaA, QIAGEN, F. Hoffmann-La Roche, PacBio, Danaher, Bio-Rad Laboratories, Promega, New England Biolabs, Zymo Research, Hologic, Active Motif, Chroma Medicine, CooperSurgical, Inherent Biosciences, Vitrolife, and Ferring Pharmaceuticals.

Key Developments:

In February 2025, New England Biolabs presented latest innovations at AGBT 2025, showcasing the NEBNext Enzymatic Methyl-seq v2 kit that enables DNA input as low as 100 picograms, expanding applications for epigenetic research. Also featured new epigenetics tools including 5hmC detection, enzymatic DNA fragmentation, and chromatin structure analysis improvements.

In January 2025, QIAGEN partnered with Genomics England to support the Generation Study, providing clinically relevant variant content for genes in a point-of-care sequencing test to screen 100,000 newborns in England for over 200 treatable conditions.

In November 2024, PacBio announced formation of the HiFi Solves Sub-fertility Consortium, uniting leading experts and leveraging HiFi sequencing technology alongside DNAstack's federated data platform to advance diagnosis and treatment of subfertility and recurrent pregnancy loss.

Components:

  • Products
  • Services

Technologies Covered:

  • DNA Methylation
  • Histone Modification
  • RNA Sequencing

Applications Covered:

  • Male Infertility
  • Female Infertility
  • Assisted Reproductive Technology (ART)
  • Predictive Diagnostics and Prognostics

End Users Covered:

  • Fertility Clinics and Hospitals
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Laboratories
  • Contract Research Organizations (CROs)

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Fertility Epigenetic Benchmarking Market, By Component

  • 5.1 Introduction
  • 5.2 Products
    • 5.2.1 Kits and Reagents
    • 5.2.2 Instruments and Accessories
  • 5.3 Services
    • 5.3.1 DNA Methylation Analysis
    • 5.3.2 Histone Modification Analysis
    • 5.3.3 Non-coding RNA Analysis
    • 5.3.4 Chromatin Structure Analysis

6 Global Fertility Epigenetic Benchmarking Market, By Technology

  • 6.1 Introduction
  • 6.2 DNA Methylation
    • 6.2.1 Bisulfite Sequencing
    • 6.2.2 Methylated DNA Immunoprecipitation Sequencing (MeDIP-Seq)
    • 6.2.3 Other DNA Methylation Technologies
  • 6.3 Histone Modification
    • 6.3.1 Chromatin Immunoprecipitation (ChIP)
    • 6.3.2 Histone Methylation Analysis
    • 6.3.3 Histone Acetylation Analysis
  • 6.4 RNA Sequencing

7 Global Fertility Epigenetic Benchmarking Market, By Application

  • 7.1 Introduction
  • 7.2 Male Infertility
  • 7.3 Female Infertility
  • 7.4 Assisted Reproductive Technology (ART)
    • 7.4.1 In Vitro Fertilization (IVF)
    • 7.4.2 Intracytoplasmic Sperm Injection (ICSI)
    • 7.4.3 Preimplantation Genetic Testing (PGT)
  • 7.5 Predictive Diagnostics and Prognostics

8 Global Fertility Epigenetic Benchmarking Market, By End User

  • 8.1 Introduction
  • 8.2 Fertility Clinics and Hospitals
  • 8.3 Academic and Research Institutes
  • 8.4 Pharmaceutical and Biotechnology Companies
  • 8.5 Diagnostic Laboratories
  • 8.6 Contract Research Organizations (CROs)

9 Global Fertility Epigenetic Benchmarking Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Illumina
  • 11.2 Thermo Fisher Scientific
  • 11.3 Merck KGaA
  • 11.4 QIAGEN
  • 11.5 F. Hoffmann-La Roche
  • 11.6 PacBio
  • 11.7 Danaher
  • 11.8 Bio-Rad Laboratories
  • 11.9 Promega
  • 11.10 New England Biolabs
  • 11.11 Zymo Research
  • 11.12 Hologic
  • 11.13 Active Motif
  • 11.14 Chroma Medicine
  • 11.15 CooperSurgical
  • 11.16 Inherent Biosciences
  • 11.17 Vitrolife
  • 11.18 Ferring Pharmaceuticals

List of Tables

  • Table 1 Global Fertility Epigenetic Benchmarking Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Fertility Epigenetic Benchmarking Market Outlook, By Component (2024-2032) ($MN)
  • Table 3 Global Fertility Epigenetic Benchmarking Market Outlook, By Products (2024-2032) ($MN)
  • Table 4 Global Fertility Epigenetic Benchmarking Market Outlook, By Kits and Reagents (2024-2032) ($MN)
  • Table 5 Global Fertility Epigenetic Benchmarking Market Outlook, By Instruments and Accessories (2024-2032) ($MN)
  • Table 6 Global Fertility Epigenetic Benchmarking Market Outlook, By Services (2024-2032) ($MN)
  • Table 7 Global Fertility Epigenetic Benchmarking Market Outlook, By DNA Methylation Analysis (2024-2032) ($MN)
  • Table 8 Global Fertility Epigenetic Benchmarking Market Outlook, By Histone Modification Analysis (2024-2032) ($MN)
  • Table 9 Global Fertility Epigenetic Benchmarking Market Outlook, By Non-coding RNA Analysis (2024-2032) ($MN)
  • Table 10 Global Fertility Epigenetic Benchmarking Market Outlook, By Chromatin Structure Analysis (2024-2032) ($MN)
  • Table 11 Global Fertility Epigenetic Benchmarking Market Outlook, By Technology (2024-2032) ($MN)
  • Table 12 Global Fertility Epigenetic Benchmarking Market Outlook, By DNA Methylation (2024-2032) ($MN)
  • Table 13 Global Fertility Epigenetic Benchmarking Market Outlook, By Bisulfite Sequencing (2024-2032) ($MN)
  • Table 14 Global Fertility Epigenetic Benchmarking Market Outlook, By Methylated DNA Immunoprecipitation Sequencing (MeDIP-Seq) (2024-2032) ($MN)
  • Table 15 Global Fertility Epigenetic Benchmarking Market Outlook, By Other DNA Methylation Technologies (2024-2032) ($MN)
  • Table 16 Global Fertility Epigenetic Benchmarking Market Outlook, By Histone Modification (2024-2032) ($MN)
  • Table 17 Global Fertility Epigenetic Benchmarking Market Outlook, By Chromatin Immunoprecipitation (ChIP) (2024-2032) ($MN)
  • Table 18 Global Fertility Epigenetic Benchmarking Market Outlook, By Histone Methylation Analysis (2024-2032) ($MN)
  • Table 19 Global Fertility Epigenetic Benchmarking Market Outlook, By Histone Acetylation Analysis (2024-2032) ($MN)
  • Table 20 Global Fertility Epigenetic Benchmarking Market Outlook, By RNA Sequencing (2024-2032) ($MN)
  • Table 21 Global Fertility Epigenetic Benchmarking Market Outlook, By Application (2024-2032) ($MN)
  • Table 22 Global Fertility Epigenetic Benchmarking Market Outlook, By Male Infertility (2024-2032) ($MN)
  • Table 23 Global Fertility Epigenetic Benchmarking Market Outlook, By Female Infertility (2024-2032) ($MN)
  • Table 24 Global Fertility Epigenetic Benchmarking Market Outlook, By Assisted Reproductive Technology (ART) (2024-2032) ($MN)
  • Table 25 Global Fertility Epigenetic Benchmarking Market Outlook, By In Vitro Fertilization (IVF) (2024-2032) ($MN)
  • Table 26 Global Fertility Epigenetic Benchmarking Market Outlook, By Intracytoplasmic Sperm Injection (ICSI) (2024-2032) ($MN)
  • Table 27 Global Fertility Epigenetic Benchmarking Market Outlook, By Preimplantation Genetic Testing (PGT) (2024-2032) ($MN)
  • Table 28 Global Fertility Epigenetic Benchmarking Market Outlook, By Predictive Diagnostics and Prognostics (2024-2032) ($MN)
  • Table 29 Global Fertility Epigenetic Benchmarking Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global Fertility Epigenetic Benchmarking Market Outlook, By Fertility Clinics and Hospitals (2024-2032) ($MN)
  • Table 31 Global Fertility Epigenetic Benchmarking Market Outlook, By Academic and Research Institutes (2024-2032) ($MN)
  • Table 32 Global Fertility Epigenetic Benchmarking Market Outlook, By Pharmaceutical and Biotechnology Companies (2024-2032) ($MN)
  • Table 33 Global Fertility Epigenetic Benchmarking Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global Fertility Epigenetic Benchmarking Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.